Inactivated influenza vaccines prepared in cell culture : National Institute for Biological Standards and Control, Potters Bar, Herts., U.K. September 26-27, 1997

F. Brown

Abstract:Part 1 Isolation and cultivation of influenza virus on mammalian cells: an overview of host cell selection, J.S. Robertson suitability of MDCK cells grown in a serum-free medium for influenza virus production, N. Kessler et al production of influenza virus in serum-free mammalian cell cultures, O.W. Merten et al growth and immuno-genicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs, E.A. Govorkova evaluation of immune responses to inactivated influenza vaccines prepared in embryonated chicken eggs and MDCK cells in a mouse model, K. Nerome et al cell culture for surveillance of influenza, M. Zambon. Part 2 Selection of vaccine strains: generation and characteristics of reassortant influenza A viruses propagated in serum-free cultured MDCK-SF1 cells, J.M.T. Voeten et al. Part 3 Scale up for vaccine production: influvac tl- a safe Madin Darby canine kidney (MDCK cell culture based influenza vaccine, R. Brands et al development of a vero cell-derived influenza whole virus vaccine, O. Kistner et al. Part 4 Clinical trials: safety, reactogenicity and immunogenicity of Madin Darby canine kidney cell-derived inactivated influenza subunit vaccine - a meta-analysis of clinical studies, A.M. Palache et al A phase I, randomised controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line, P.B. Percheson et al. Part 5 General regulatory issues I - cell substrates: experience with vero cell at Pasteur Merieux Connaught, B.J. Montagnon et al quality assurance for cell substrates, G.N. Stacey, P. Phillips WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals - application to influenza vaccine production, E. Griffiths ICH guidelines and PhEur monographs on derivation and characterization of cell substrates used for production of biotechnological/biological products, R. Dobbelaerg. Part 6 General regulatory issues II - cell culture influenza vaccines: regulatory perspective in the United States on cell cultures for production of inactivated influenza virus vaccines, R.A. Levandowski cell culture influenza vaccine - an Australian perspective, L. Chang et al the influence of the host cell on standardization the neuraminidase content of influenza vaccines, L. Gerentes et al.

Biology,Medicine